Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alteplase.

D de Bono1

  • 1University of Leicester, Faculty of Medicine, Clinical Sciences Wing, Glenfield General Hospital, Leicester, LE3 9QP, UK.

Expert Opinion on Investigational Drugs
|August 1, 1997
PubMed
Summary
This summary is machine-generated.

Alteplase, a recombinant tissue plasminogen activator (rt-PA), is a clinically effective thrombolytic agent for acute myocardial infarction. This review assesses its current therapeutic status and properties.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spring Books: Cardiological salad bowl.

British medical journal (Clinical research ed.)·2010
Same author

Low proportion of familial dilated cardiomyopathy in an arab population with a high prevalence of consanguineous marriages.

Acta paediatrica (Oslo, Norway : 1992)·2002
Same author

Prevalence and aetiology of heart failure in an Arab population.

European journal of heart failure·2001
Same author

Catecholamine levels in heart failure due to dilated cardiomyopathy and their relationship to the severity of heart failure.

European journal of heart failure·2000
Same author

Coronary artery disease: combined stress MR imaging protocol-one-stop evaluation of myocardial perfusion and function.

Radiology·2000
Same author

Investigation and management of stable angina: revised guidelines 1998. Joint Working Party of the British Cardiac Society and Royal College of Physicians of London.

Heart (British Cardiac Society)·1999

Area of Science:

  • Biochemistry
  • Pharmacology
  • Cardiology

Background:

  • Alteplase (recombinant human tissue type plasminogen activator, rt-PA) is a key thrombolytic agent.
  • It was identified in 1975 and licensed for acute myocardial infarction in 1986.

Purpose of the Study:

  • To assess the current clinical effectiveness of alteplase as a thrombolytic agent.
  • To briefly review its biochemical, physiological, and pharmacological properties.

Main Methods:

  • Literature review focusing on clinical trials and therapeutic applications.
  • Analysis of biochemical, physiological, and pharmacological data.

Main Results:

  • Alteplase has demonstrated significant clinical efficacy in treating acute myocardial infarction.
  • Its properties support its role as a primary thrombolytic therapy.

    • Conclusions:

    • Alteplase remains a vital and effective thrombolytic treatment.
    • Continued understanding of its properties is crucial for optimal patient outcomes.